GlassScriptPhysician profile
Virginia Aann Jethro
NPI 1114988292
$212,893.32
in general payments reported to CMS, 2019-2025
58 companies · $52K in 2025
The $52K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48K · 2022: $30K · 2023: $54K · 2024: $29K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $99K · Honoraria: $14K · Food and Beverage: $13K · Travel and Lodging: $7,964 · Consulting Fee: $1,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $98,637.50 |
| Honoraria | $13,650.00 |
| Food and Beverage | $12,907.91 |
| Travel and Lodging | $7,964.21 |
| Consulting Fee | $1,835.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $175,691.82 | 2021-2025 | |
| Axsome Therapeutics, INC. | $16,790.15 | 2024-2025 | Symbravo, Sunosi |
| Pfizer INC. | $4,479.13 | 2022-2025 | |
| Ucb, INC. | $2,219.20 | 2022-2025 | Briviact, Fintepla, Nayzilam |
| Lundbeck LLC | $2,162.34 | 2022-2025 | Vyepti |
| Allergan, INC. | $1,289.66 | 2021-2022 | |
| Amgen INC. | $956.03 | 2021-2025 | Uplizna, Aimovig |
| Biogen, INC. | $739.95 | 2021-2025 | Tysabri, Vumerity, Leqembi |
| Eisai INC. | $678.46 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $613.88 | 2021-2025 | |
| Tg Therapeutics, INC. | $604.00 | 2023-2025 | |
| Impel Pharmaceuticals INC. | $574.38 | 2022-2023 | Trudhesa |
| Argenx US, INC. | $546.62 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $546.61 | 2021-2025 | Ultomiris, Soliris |
| Neurelis, INC. | $528.50 | 2021-2025 | Valtoco |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Jethro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.